Clinical trialPhase 3
ACCLAIM-CTA
NCT07613294
Стартовал 02.06.2026: randomized double-blind placebo-controlled, N≈252, primary endpoint percent change in coronary noncalcified plaque volume.
No news refers to this card yet.
Also in the catalogue
- OCEAN(a)-OutcomesClinical trial
- CORALreef OutcomesClinical trial
- ACCLAIM-Lp(a)Clinical trial
- BROADWAY (obicetrapib)Clinical trial
- Lp(a)HORIZON (pelacarsen)Clinical trial
- REMBRANDTClinical trial
Scales
Identifiers
- NCT
- NCT07613294
Original sources
Details
- Phase
- Phase 3
A catalog card describes research; it is not medical advice. Decisions about treatment are made with a doctor.